Related references
Note: Only part of the references are listed.Learning from the past: development of safe and effective COVID-19 vaccines
Shan Su et al.
NATURE REVIEWS MICROBIOLOGY (2021)
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Merryn Voysey et al.
LANCET (2021)
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
Denis Y. Logunov et al.
LANCET (2021)
Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial
Peter Richmond et al.
LANCET (2021)
Viral targets for vaccines against COVID-19
Lianpan Dai et al.
NATURE REVIEWS IMMUNOLOGY (2021)
A distinct name is needed for the new coronavirus
Shibo Jiang et al.
LANCET (2020)
A Novel Coronavirus from Patients with Pneumonia in China, 2019
Na Zhu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2
Qihui Wang et al.
CELL (2020)
Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses
Ning Wang et al.
FRONTIERS IN MICROBIOLOGY (2020)
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
Feng-Cai Zhu et al.
LANCET (2020)
A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS
Lianpan Dai et al.
CELL (2020)
The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients
Lakshmanane Premkumar et al.
SCIENCE IMMUNOLOGY (2020)
COVID-19 Vaccines: Warp Speed Needs Mind Melds, Not Warped Minds
John P. Moore et al.
JOURNAL OF VIROLOGY (2020)
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
Feng-Cai Zhu et al.
LANCET (2020)
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Pedro M. Folegatti et al.
LANCET (2020)
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
Mark J. Mulligan et al.
NATURE (2020)
An mRNA Vaccine against SARS-CoV-2-Preliminary Report
L. A. Jackson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
Denis Y. Logunov et al.
LANCET (2020)
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Ugur Sahin et al.
NATURE (2020)
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
Edward E. Walsh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
E. J. Anderson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
Cheryl Keech et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Maheshi N. Ramasamy et al.
LANCET (2020)
Bat-to-human: spike features determining 'host jump' of coronaviruses SARS-CoV, MERS-CoV, and beyond
Guangwen Lu et al.
TRENDS IN MICROBIOLOGY (2015)
Share Paper
